Advertisement
Advertisement

NBIX

NBIX logo

Neurocrine Biosciences Inc

156.70
USD
Sponsored
+1.20
+0.77%
May 22, 16:00 UTC -4
Closed
exchange

After-Market

158.00

+1.30
+0.83%

Neurocrine Biosciences Inc Profile

About

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.

Info & Links

CEO

Kyle W. Gano

Headquarters

6027 Edgewood Bend Court
San Diego, CA 92130, UNITED STATES

Industry

Medical Drugs

Sector

Medical

Website

www.neurocrine.com

Auditor

Ernst & Young LLP

Share holders

35

Employees

2,000

Neurocrine Biosciences Inc Statistics

Valuation Measures

Market Capitalization2

15.89B

Enterprise Value

15.62B

Enterprise Value/EBITDA(ttm)

19.38

Price to Earnings Ratio(ttm)

28.56

Price to Sales(ttm)

4.62

Price to Book(mrq)

4.03

Price to Cash(ytd)

26.26

Profitability

Gross Margin(ttm)

98.20%

Operating Margin(ttm)

16.54%

Profit Margin(ttm)

15.61%

Return on Equity(ttm)

16.48%

Return on Invested Capital(ttm)

16.00%

Return on Assets(ttm)

11.49%

Income Statement

Revenue(ttm)

3.10B

Revenue Per Share(ttm)

30.85

Gross Profit(ttm)

3.05B

EBITDA(ttm)3

806.00M

Net Income Available to Common(ttm)

668.60M

Diluted EPS(ttm)

4.66

Share Statistics

Beta (5Y Monthly)

0.35

52-Week Change

31.55%

S&P 500 52-Week Change

28.79%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

100.55M

Dividend Yield

0.00%

Float4

95.55M

% Held by Insiders

4.80%

% Held by Institutions

92.59%

Balance Sheet

Total Cash(mrq)

1.32B

Total Cash Per Share(mrq)

13.09

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

3.39%

Quick Ratio(mrq)

3.30%

Book Value Per Share(mrq)

32.50

Cash Flow

Operating Cash Flow Per Share(ytd)

7.64

Free Cash Flow(ytd)

748.70M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement